Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
NCT00136214 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2018-07-12
Summary
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
Conditions
- Hepatitis C
Interventions
- DIAGNOSTIC_TEST
-
MR brain and neuropsychiatric tests
Sponsors & Collaborators
-
Schering-Plough
collaborator INDUSTRY -
Beth Israel Deaconess Medical Center
lead OTHER
Principal Investigators
-
Nezam Afdhal, MD · Beth Israel Deaconess Medical Center
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-03-31
- Primary Completion
- 2008-01-31
- Completion
- 2008-03-31
Countries
- United States
Study Locations
More Related Trials
-
Neuropsychiatric Effects of Interferon-Alpha and Ribavirin
NCT00001547 ·Status: COMPLETED
-
Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication
NCT00188201 ·Status: UNKNOWN
-
Psychobiological Characterization of Depression in Hepatitis C
NCT01492478 ·Status: UNKNOWN
-
Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy
NCT02469012 ·Status: UNKNOWN ·Phase: NA
-
Effects of HIV and Hepatitis C Virus on the Brain
NCT00494936 ·Status: COMPLETED
-
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
NCT02650024 ·Status: COMPLETED
-
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
NCT00723892 ·Status: COMPLETED
-
Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin
NCT00196664 ·Status: COMPLETED ·Phase: PHASE3
-
Hepatitis C Translating Initiatives for Depression Into Effective Solutions
NCT01143896 ·Status: COMPLETED ·Phase: NA
-
VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients
NCT00108563 ·Status: COMPLETED ·Phase: PHASE4
-
Improving Quality of Life for Veterans Undergoing Interferon Treatment
NCT00117559 ·Status: COMPLETED ·Phase: NA
-
Reducing Depressive Symptoms During HCV Therapy: A Randomized Study
NCT00495768 ·Status: UNKNOWN ·Phase: NA
-
Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C
NCT00209118 ·Status: COMPLETED ·Phase: NA
-
P300 in Early Cognitive Impairment in Hepatitis C Virus
NCT04389268 ·Status: COMPLETED
-
Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related
NCT03313154 ·Status: COMPLETED
-
Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients
NCT00655226 ·Status: TERMINATED ·Phase: NA
-
Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy
NCT00351871 ·Status: COMPLETED ·Phase: PHASE4
-
A Health Intervention to Prevent Depression Hepatitis C Patients
NCT01890083 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1
NCT00218556 ·Status: COMPLETED ·Phase: NA
-
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
NCT01405027 ·Status: COMPLETED ·Phase: PHASE4
-
Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
NCT00674492 ·Status: COMPLETED
-
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
NCT00166296 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
NCT01465919 ·Status: TERMINATED ·Phase: PHASE4
-
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
NCT00136318 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents
NCT03508115 ·Status: COMPLETED